NOVOCURE LTD's ticker is NVCR and the CUSIP is G6674U108. A total of 198 filers reported holding NOVOCURE LTD in Q2 2019. The put-call ratio across all filers is 0.51 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2019 | $586,000 | -31.9% | 7,840 | -42.4% | 0.02% | -29.6% |
Q2 2019 | $860,000 | -89.5% | 13,600 | -91.3% | 0.03% | -89.2% |
Q3 2018 | $8,165,000 | +503.0% | 155,817 | +260.1% | 0.25% | +445.7% |
Q2 2018 | $1,354,000 | +81.0% | 43,272 | +0.1% | 0.05% | +64.3% |
Q2 2017 | $748,000 | – | 43,211 | – | 0.03% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Invus Financial Advisors, LLC | 350,884 | $24,386,000 | 14.72% |
HARTLINE INVESTMENT CORP/ | 335,191 | $58,001,000 | 8.32% |
Deep Track Capital, LP | 1,341,300 | $93,220,000 | 6.13% |
MORGAN JESS S & CO INC | 48,345 | $3,360,000 | 3.48% |
Taylor Frigon Capital Management LLC | 68,908 | $4,789,000 | 2.49% |
HighVista Strategies LLC | 28,007 | $1,946,000 | 1.18% |
Private Harbour Investment Management & Counsel, LLC | 13,106 | $911,000 | 1.01% |
Lloyd Park, LLC | 9,325 | $648,000 | 0.68% |
Baillie Gifford | 9,116,230 | $633,578,000 | 0.65% |
HAP Trading, LLC | 110,900 | $10,575,000 | 0.53% |